Husam Alsadi
Overview
Explore the profile of Husam Alsadi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
4
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Saib I, Alahmari B, Alsadi H, Alaskar A, Hejazi A, Salama H, et al.
Transplant Cell Ther
. 2024 Nov;
31(1):30.e1-30.e8.
PMID: 39522720
Hematopoietic stem cell transplantation (HCT) remains the sole well-established curative option for patients with sickle cell disease (SCD). Nonmyeloablative conditioning has been used to improve outcomes and reduce toxicities in...
2.
Damlaj M, Alahmari B, Alaskar A, Alhejazi A, Alsadi H, Ahmed M, et al.
Am J Hematol
. 2024 Mar;
99(6):1023-1030.
PMID: 38488686
Allogeneic hematopoietic stem cell transplant (HSCT) for adults with severe sickle cell disease (SCD) is potentially curative but not commonly utilized therapy due to complications such as graft failure (GF)...
3.
Alzahrani R, Alzahrani M, Shuraim W, AlDibasi O, Albarrak K, Habib A, et al.
Transplant Proc
. 2024 Jan;
56(1):186-190.
PMID: 38242760
Background: Respiratory viral infections (RVIs) commonly cause morbidity and mortality in hematopoietic stem cell transplant (HSCT) recipients. This study aimed at the prevalence of RVIs in adult HSCT recipients and...
4.
Aljaafri B, Albawardi M, Alghamdi A, Altowairgi K, Alhoshan Y, Alahmari B, et al.
Hematol Oncol Stem Cell Ther
. 2023 Aug;
17(1):37-42.
PMID: 37581462
Background: Sickle cell disease (SCD) is frequently inherited worldwide. The severity of SCD ranges from mild to severe, and the disease involves multiple complications, including pulmonary hypertension, stroke, recurrent vaso-occlusive...
5.
Damlaj M, Tlayjeh M, Damlaj A, Alahmari B, Alsadi H, Ahmed M, et al.
Bone Marrow Transplant
. 2023 Jul;
58(10):1160-1162.
PMID: 37464089
No abstract available.
6.
Mahmoud E, Alzahrani M, Loutfi S, Alqahatani H, Bosaeed M, Ahmed A, et al.
Cureus
. 2022 Dec;
14(11):e31762.
PMID: 36569688
Objectives We evaluated liposomal amphotericin B versus voriconazole for the treatment of invasive pulmonary aspergillosis (IPA) in patients with hematological malignancy or hematopoietic stem cell transplantation (HSCT). Methods This retrospective...
7.
Saleh A, Alghamdi A, Alzahrani M, Alahmari B, Alhejazi A, Alaskar A, et al.
Bone Marrow Transplant
. 2022 May;
57(7):1201-1203.
PMID: 35501564
No abstract available.
8.
Damlaj M, Alahmari B, Alaskar A, Alhejazi A, Alsadi H, Shehab-Eddine I, et al.
Bone Marrow Transplant
. 2022 Jan;
57(2):319-322.
PMID: 35022534
No abstract available.
9.
Alzahrani M, Damlaj M, Essa M, Alahmari B, Alaskar A, Hejazi A, et al.
Bone Marrow Transplant
. 2021 Nov;
57(2):292-294.
PMID: 34743184
No abstract available.
10.
El Fakih R, Alhayli S, Ahmed S, Shaheen M, Chaudhri N, Alsharif F, et al.
Transplant Cell Ther
. 2021 Jun;
27(10):851.e1-851.e6.
PMID: 34126277
The recommended therapy for severe aplastic anemia (SAA) in younger patients with a matched sibling donor (MSD) is allogeneic hematopoietic cell transplantation (allo-HCT). A number of conditioning regimens and protocols...